KDR, kinase insert domain receptor, 3791

N. diseases: 623; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.050 Biomarker disease BEFREE Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. 30719715 2019
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.050 Biomarker disease BEFREE This study tested the hypothesis that vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 contribute to bone cancer pain regulation associated with spinal central sensitization. 31567367 2019
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.050 Biomarker disease BEFREE To investigate the clinical significance of vascular endothelial growth factor receptor-2 (VEGFR2) and programmed death ligand-1 (PD-L1) in osteosarcoma, we analyzes their expression levels in 93 osteosarcoma specimens by immunohistochemistry. 29225166 2018
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.050 Biomarker disease BEFREE Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. 28837148 2017
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone
0.050 AlteredExpression disease BEFREE It has been reported that VEGFR expression correlates with the outcome of patients with osteosarcoma and circulating VEGF level has been associated with the development of lung metastasis. 28656259 2017